X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock Has Average Target Price of $11.25 According to Analysts

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $11.25.

Several brokerages recently issued reports on XFOR. Weiss Ratings upgraded X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. Wells Fargo & Company assumed coverage on X4 Pharmaceuticals in a research note on Friday, July 10th. They set an “overweight” rating and a $11.00 price objective on the stock.

Insider Buying and Selling at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, Chairman Adam Craig sold 47,436 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $210,615.84. Following the transaction, the chairman owned 328,651 shares of the company’s stock, valued at approximately $1,459,210.44. The trade was a 12.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO David Kirske sold 11,767 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $2.86, for a total value of $33,653.62. Following the completion of the transaction, the chief financial officer owned 155,983 shares of the company’s stock, valued at $446,111.38. This trade represents a 7.01% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 83,779 shares of company stock worth $353,387. Insiders own 1.13% of the company’s stock.

Institutional Trading of X4 Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Empery Asset Management LP purchased a new position in X4 Pharmaceuticals in the 4th quarter worth approximately $35,804,000. Perceptive Advisors LLC boosted its stake in shares of X4 Pharmaceuticals by 6.7% during the first quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock valued at $27,826,000 after purchasing an additional 423,196 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of X4 Pharmaceuticals during the second quarter valued at approximately $917,000. Bank of America Corp DE boosted its stake in shares of X4 Pharmaceuticals by 321.3% during the first quarter. Bank of America Corp DE now owns 150,676 shares of the company’s stock valued at $622,000 after purchasing an additional 114,915 shares during the period. Finally, Squarepoint Ops LLC bought a new position in shares of X4 Pharmaceuticals in the second quarter worth approximately $313,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Trading Down 5.8%

Shares of XFOR stock opened at $2.45 on Thursday. X4 Pharmaceuticals has a fifty-two week low of $2.43 and a fifty-two week high of $4.83. The company has a debt-to-equity ratio of 0.49, a quick ratio of 11.02 and a current ratio of 11.30. The stock has a 50 day simple moving average of $3.60 and a two-hundred day simple moving average of $3.90. The company has a market cap of $242.91 million, a P/E ratio of -2.04 and a beta of 0.46.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%. The firm had revenue of $8.81 million for the quarter, compared to analysts’ expectations of $2.42 million. Research analysts forecast that X4 Pharmaceuticals will post -0.67 earnings per share for the current year.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company’s research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues.

X4’s primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome.